Sign Up Today and Learn More About Faraday Pharmaceuticals Stock
Invest in or calculate the value of your shares in Faraday Pharmaceuticals or other pre-IPO companies through EquityZen's platform.
Faraday Pharmaceuticals Stock (FAPH)
Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury.
About Faraday Pharmaceuticals Stock
Founded
2014
Headquarters
Seattle, WA, US
Industries
Messaging and Telecommunications, Sports, Content and Publishing
Faraday Pharmaceuticals Press Mentions
Stay in the know about the latest news on Faraday Pharmaceuticals
Global Myocardial Infarction Market to Surge to US$ 3.64 Billion by 2033 as Demand for Advanced Cardiovascular Treatments Escalates - ResearchAndMarkets.com
businesswire • Apr 11, 2025
Myocardial Infarction Market Forecast Report 2025-2033 Featuring Major Players - Pfizer, BMS, AstraZeneca, Merck KGaA., Daiichi Sankyo, Novartis, Genentech, Amgen, Regeneron, Takeda
globenewswire • Apr 02, 2025
Faraday Pharmaceuticals to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
biospace • Feb 06, 2025
Faraday Pharmaceuticals to Participate in Jefferies London Healthcare Conference
globenewswire • Nov 06, 2024
Faraday Pharmaceuticals to Host KOL Webinar on the Unmet
globenewswire • Aug 03, 2024
Faraday Pharmaceuticals Management
Leadership team at Faraday Pharmaceuticals
CEO
Stephen A. Hill
General Counsel & Corporate Secretary
Patrick C. Rock
Join now and verify your accreditation status to gain access to:
- Faraday Pharmaceuticals Current Valuation
- Faraday Pharmaceuticals Stock Price
- Faraday Pharmaceuticals Management
- Available deals in Faraday Pharmaceuticals and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Faraday Pharmaceuticals Cap Table and Funding History by Share Class and Liquidity Preferences
- Faraday Pharmaceuticals Revenue and Financials
- Faraday Pharmaceuticals Highlights
- Faraday Pharmaceuticals Business Model
- Faraday Pharmaceuticals Risk Factors
- Faraday Pharmaceuticals Research Report from SACRA Research
Trading Faraday Pharmaceuticals Stock
How to invest in Faraday Pharmaceuticals stock?
Accredited investors can buy pre-IPO stock in companies like Faraday Pharmaceuticals through EquityZen funds. These investments are made available by existing Faraday Pharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Faraday Pharmaceuticals stock?
Shareholders can sell their Faraday Pharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
